Harmony Biosciences Holdings, I
HRMY
Positions held
Your positionsHRMY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Harmony Biosciences is strategically positioned in the growing biotechnology sector, focusing on innovative treatments for neurological conditions, which enhances its competitive edge.
- In Q2 2026, Harmony reported a revenue increase of 21% compared to the prior quarter, reaching $261 million.
- The operating margin expanded to 34.2% in Q2 2026, reflecting improved operational efficiency.
- Despite its growth, Harmony faces challenges with a high debt-to-equity ratio of 16.031, which may impact financial stability.
- The gross margin decreased to 75.8% in Q2 2026 from 79.3% in the prior quarter, indicating potential pricing pressures.
- The stock has a neutral score of 5.00, with signals suggesting a bearish trend in the market.
Fundamentals
| Market cap | $2.31B | Enterprise value | $1.80B | Trailing P/E | 12.77 | Forward P/E | 5.65 |
| PEG | — | Price / book | 2.30 | Beta | 1.01 | Dividend yield | 0.00% |
| Revenue growth | 30.3% | Earnings growth | 88.2% | Gross margin | 75.4% | Operating margin | 34.2% |
| Profit margin | 18.9% | ROE | 20.5% | ROA | 11.6% | Debt / equity | 0.16 |
| Current ratio | 3.48 | Free cash flow | $182.84M | Analyst recommendation | buy | Mean target | $47.64 |
| 52w high | $43.49 | 52w low | $25.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $261M | $215M | $244M | $239M | $200M |
| Op margin | 34.2% | 17.3% | 15.8% | 27.3% | 24.0% |
| Net income | $75.4M | $32.5M | $22.5M | $50.9M | $39.8M |
| Gross margin | 75.8% | 79.3% | 71.9% | 75.1% | 81.0% |
| Gross profit | $198M | $171M | $175M | $180M | $162M |
| Operating income | $89.3M | $37.3M | $38.6M | $65.5M | $48.2M |
- Revenue +21% vs prior quarter ($261M vs $215M).
- Gross margin 75.8% (was 79.3% prior quarter).
- Operating margin expanded to 34.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $868M | $715M | $582M | $438M | — |
| Op margin | 24.0% | 26.7% | 33.0% | 27.4% | — |
| Net income | $159M | $145M | $129M | $181M | — |
| Gross margin | 77.2% | 78.1% | 79.2% | 80.9% | — |
| Gross profit | $670M | $558M | $461M | $354M | — |
| Operating income | $208M | $191M | $192M | $120M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Harmony Biosciences (HRMY) Heads To European Narcolepsy Days With New Phase 3 Data
2026-10-08 · Harmony Biosciences (HRMY) Stock Looks Below Fair Value As Shares Rose 48%
2026-10-08 · Harmony BioSciences' Wakix Franchise, Pipeline Offer Multiple Value Drivers, Oppenheimer Says
2026-10-06 · HRMY vs. CSLLY: Which Stock Is the Better Value Option?
2026-10-06 · Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
2026-10-01 · Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
2026-10-01 · Deutsche Bank Lifts Price Target on Harmony Biosciences Holdings to $42 From $39, Keeps Hold Rating
2026-09-18 · Harmony Biosciences Holdings Insider Sold Shares Worth $1,655,416, According to a Recent SEC Filing
2026-09-09 · Harmony Biosciences Holdings Insider Sold Shares Worth $1,453,169, According to a Recent SEC Filing
2026-09-04 · Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
2026-09-03 · Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
2026-09-03 · Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Price (daily)
Full chart · RSI · MACD · patterns